Clinical Trial Update: To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics and safety of TQD3524 injected in adults with renal impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Caused By Multi-drug Resistant Gram-negative Bacteria

Drugs mentioned

• TQD3524

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Multi-resistant Gram-negative Bacteria Cause Infection | Phase 1 | Status: COMPLETED